Arvinas Appoints Jared Freedberg as General Counsel
NEW HAVEN, Conn., Jan. 16, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Jared Freedberg, J.D., has joined the company as General Counsel.
Related news for (ARVN)
- Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
- Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
- Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
- Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
- Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update